Cargando…
1110. A multicenter Evaluation of Outcomes Associated With Oral Vancomycin Dose in Patients With Clostridium difficile Infection
BACKGROUND: Clostridium difficile infection (CDI) is a significant cause of morbidity and mortality. IDSA guidelines recommend oral vancomycin (VAN) for the treatment of CDI, although doses used in practice vary substantially. The purpose of this study was to determine differences in outcomes betwee...
Autores principales: | Bidell, Monique, Novak, Gregory, Singh, Gurkirat, Bratek, Benjamin, Duru, Odirichukwu, Mitchell, Colby, O’Donnell, J Nicholas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254310/ http://dx.doi.org/10.1093/ofid/ofy210.944 |
Ejemplares similares
-
1110. In Vivo Pharmacodynamics of Vancomycin Against Staphylococci in Young Infants
por: Gwee, Amanda, et al.
Publicado: (2021) -
Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
por: Bunnell, Kristen L., et al.
Publicado: (2017) -
Oral vancomycin desensitisation to treat Clostridium difficile infection in a vancomycin allergic patient
por: Mahabir, Shanti, et al.
Publicado: (2013) -
Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection
por: Shah, Sunish, et al.
Publicado: (2017) -
Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)